Imidazoline 1 receptor Inhibitors
1 drugsAbout Imidazoline 1 receptor
The Imidazoline 1 receptor (I1 receptor) is a protein involved in various biological processes, making it a potential therapeutic target. Its precise physiological roles are still being elucidated, but it is of growing interest in pharmacological research.
Currently, there is no genetic evidence directly linking the I1 receptor to specific diseases. Modulating its activity could potentially offer therapeutic benefits, but further research is needed to fully understand its functions.
There is one FDA-approved drug, TEPMETKO (small molecule), targeting the I1 receptor, developed by EMD SERONO INC. It was first approved in 2021 for an indication categorized as "Other."
Top Imidazoline 1 receptor Drugs
EMD SERONO INC is the only company with an approved drug targeting the I1 receptor.
Low competition suggests a potential first-mover advantage for new entrants in this space.
Imidazoline 1 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Imidazoline 1 receptor, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel therapeutic approaches.
Imidazoline 1 receptor Clinical Trials 21 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Imidazoline 1 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 13 | 8 | 2 | 3 | 80% |
| Phase 2 | 7 | 1 | 1 | 5 | 50% |
| Phase 3 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Imidazoline 1 receptor Drug Approval Timeline (2021 - 2021)
Metastatic non-small cell lung cancer (NSCLC) harboring m...
The first and only drug, TEPMETKO, was approved in 2021.
Recent approval suggests renewed interest, but saturation is low, indicating growth potential.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 12 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Imidazoline 1 receptor. A trial counts if an approved drug acting on Imidazoline 1 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.